MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

Cancer

09/152021

Clinical trials show promise for Innocell cancer vaccine

PhotonPharma’s Innocell involves sampling a patient’s tumor cells, inactivating them so that they are unable to replicate, then administering them back to the patient.

Read more
09/032021

New approach enhances vaccination

Vaccines must elicit immune responses of a sufficient magnitude and quality to prevent or treat disease. While existing vaccine technologies are capable of achieving this goal for many diseases, these strategies have thus far proven inadequate against global threats like HIV and cancer.

Read more
09/032021

New compound inhibits pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortalities of all malignancies, with aggressive biology, resistance to therapeutic agents, and a mere 5-year survival of 8-9%.

Read more
08/312021

Therapeutic cancer vaccine platform is customizable

B cells are primarily known for their robust adaptive immune response through antibody production; however, they are often overlooked among the body’s professional antigen-presenting cell (APC) populations.

Read more
08/312021

RNA-binding protein inhibitors slow tumor growth in metastatic cancers

Despite recent therapeutic advances in cancer treatment, metastatic cancer remains the primary cause of cancer deaths.

Read more
08/312021

Human chimeric antigen receptor neutrophils to treat cancer

Researchers at Purdue University have developed chimeric antigen receptor (CAR) neutrophils for the targeted treatment of cancer.

Read more
08/312021

Selective GRK5 inhibitors can treat heart failure, breast cancer

Researchers at Purdue University have developed selective small molecule inhibitors of G protein-coupled receptor kinase 5 (GRK5) for preventing heart failure and treating breast cancer.

Read more
08/202021

New mitochondria-targeted therapeutics will help lung, other cancers

Medical College of Wisconsin inventors have developed novel small molecule therapeutics that will help treat small cell lung cancer, among other cancers.

Read more
08/112021

Small molecule shows first-in-human MoA for salivary gland cancers

SVC112 is a late-preclinical stage asset with potent single agent activity in genetically-defined models of salivary gland cancer, a neglected and orphan disease with no approved targeted or immunotherapy agents.

Read more
07/272021

New approach improves CAR T cancer therapies

Mayo Clinic researchers have developed a novel regimen by which oncolytic virotherapy can be used as a potent immunological adjuvant to improve the efficacy of CAR T cell therapy against solid tumors.

Read more
Older Entries

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights

An error has occured.